133 related articles for article (PubMed ID: 25328014)
1. Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.
Kim MS; Lim DY; Kim JE; Chen H; Lubet RA; Dong Z; Bode AM
Mol Carcinog; 2015 Dec; 54(12):1596-604. PubMed ID: 25328014
[TBL] [Abstract][Full Text] [Related]
2. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).
Vedell PT; Lu Y; Grubbs CJ; Yin Y; Jiang H; Bland KI; Muccio DD; Cvetkovic D; You M; Lubet R
Mol Pharmacol; 2013 Mar; 83(3):698-708. PubMed ID: 23292798
[TBL] [Abstract][Full Text] [Related]
3. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.
Grubbs CJ; Lubet RA; Atigadda VR; Christov K; Deshpande AM; Tirmal V; Xia G; Bland KI; Eto I; Brouillette WJ; Muccio DD
Carcinogenesis; 2006 Jun; 27(6):1232-9. PubMed ID: 16344269
[TBL] [Abstract][Full Text] [Related]
5. Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics.
Melo N; Belyaeva OV; Berger WK; Halasz L; Yu J; Pilli N; Yang Z; Klyuyeva AV; Elmets CA; Atigadda V; Muccio DD; Kane MA; Nagy L; Kedishvili NY; Renfrow MB
J Biol Chem; 2023 Jan; 299(1):102746. PubMed ID: 36436565
[TBL] [Abstract][Full Text] [Related]
6. UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
Garner EF; Stafman LL; Williams AP; Aye JM; Goolsby C; Atigadda VR; Moore BP; Nan L; Stewart JE; Hjelmeland AB; Friedman GK; Beierle EA
J Neurooncol; 2018 Nov; 140(2):209-224. PubMed ID: 30132166
[TBL] [Abstract][Full Text] [Related]
7. A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.
Williams AP; Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
J Surg Res; 2018 Aug; 228():54-62. PubMed ID: 29907230
[TBL] [Abstract][Full Text] [Related]
8. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
Boerma LJ; Xia G; Qui C; Cox BD; Chalmers MJ; Smith CD; Lobo-Ruppert S; Griffin PR; Muccio DD; Renfrow MB
J Biol Chem; 2014 Jan; 289(2):814-26. PubMed ID: 24187139
[TBL] [Abstract][Full Text] [Related]
9. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention.
Kapetanovic IM; Horn TL; Johnson WD; Cwik MJ; Detrisac CJ; McCormick DL
Int J Toxicol; 2010; 29(2):157-64. PubMed ID: 20335511
[TBL] [Abstract][Full Text] [Related]
10. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.
Yen WC; Prudente RY; Corpuz MR; Negro-Vilar A; Lamph WW
Br J Cancer; 2006 Mar; 94(5):654-60. PubMed ID: 16495926
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2015 Jul; 14(7):1559-69. PubMed ID: 25944918
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells.
Fu J; Wang W; Liu YH; Lu H; Luo Y
BMC Cancer; 2011 Jun; 11():227. PubMed ID: 21649908
[TBL] [Abstract][Full Text] [Related]
13. Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
Li W; Liu Z; Zhao C; Zhai L
Oncol Rep; 2015 Sep; 34(3):1345-52. PubMed ID: 26134759
[TBL] [Abstract][Full Text] [Related]
14. Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis.
Wu L; Chaudhary SC; Atigadda VR; Belyaeva OV; Harville SR; Elmets CA; Muccio DD; Athar M; Kedishvili NY
PLoS One; 2016; 11(4):e0153556. PubMed ID: 27078158
[TBL] [Abstract][Full Text] [Related]
15. Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Chen YJ; Lin KN; Jhang LM; Huang CH; Lee YC; Chang LS
Chem Biol Interact; 2016 May; 252():131-40. PubMed ID: 27087131
[TBL] [Abstract][Full Text] [Related]
16. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Yen WC; Lamph WW
Mol Cancer Ther; 2005 May; 4(5):824-34. PubMed ID: 15897247
[TBL] [Abstract][Full Text] [Related]
17. Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.
Fan L; Zhang Y; Zhou Q; Liu Y; Gong B; Lü J; Zhu H; Zhu G; Xu Y; Huang G
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30401729
[TBL] [Abstract][Full Text] [Related]
18. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
19. Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
Han JS; Crowe DL
BMC Cancer; 2010 Nov; 10():629. PubMed ID: 21080969
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2016 May; 15(5):911-21. PubMed ID: 26873726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
